Table 2.

Analysis of the DRB1-DQA1-DQB1 second alleles in heterozygous DRB1*03/x (DR3-DQ2) and HLA DRB1*04/x (DR4-DQ8) patient and controls, carrying one high-risk allele. Data were separately analysed for HLA DRB1*03/x (DR3-DQ2) and DRB1*04/x (DR4/DQ8) heterozygous groups.

Patients with DRB1*03/x
DRB1*	DQA1*	DQB1*	Controls	T1D Patients	Odds Ratio (CI)	p
			n (%)	n (%)
01:01	01:01	05:01	359 (10.5)	11 (29.7)	3.62 (1.76; 7.39)	<0.001
07:01	02:01	02:02	332 (9.7)	2 (5.4)	0.53 (0.13; 1.98)	0.575
08:01	04:01/02	04:02	105 (3.1)	5 (13.5)	4.95 (2.05; 12.22)	0.006
09:01	03:02	03:03	23 (0.7)	4 (10.8)	17.95 (6.37; 53.99)	<0.001
12:01	05:05	03:01	94 (2.7)	2 (5.4)	2.03 (0.47; 7.78)	0.274
13:01	01:03	06:03	281 (8.2)	2 (5.4)	0.64 (0.15; 2.39)	0.765
13:02	01:02	06:04	142 (4.1)	3 (8.1)	2.04 (0.65; 6.03)	0.200
16:01	01:02	05:02	120 (3.5)	8 (21.6)	7.61 (3.56; 16.52)	<0.001
others			1972 (57.5)
Patients with DRB1*04/x (DRB1*04 combining the DRB1*04:01/02/04/05 alleles, see text)
DRB1*	DQA1*	DQB1*	Controls	T1D Patients	Odds Ratio (CI)	p
			n (%)	n (%)
01:01	01:01	05:01	291 (11.6)	15 (25.0)	2.55 (1.39; 4.53)	0.001
01:02	01:01	05:01	36 (1.4)	2 (3.3)	2.37 (0.55; 9.34)	0.221
04:01	03:02	03:01	44 (1.8)	2 (3.3)	1.94 (0.45; 7.44)	0.291
07:01	02:01	02:02	260 (10.3)	3 (5.0)	0.46 (0.15; 1.35)	0.276
07:01	02:01	03:03	100 (4.0)	1 (1.7)	0.41 (0.04; 2.24)	0.730
08:01	04:01/02	04:02	202 (8.0)	14 (23.3)	3.48 (1.91; 6.38)	<0.001
08:04	04:01	04:02	8 (0.3)	1 (1.7)	5.31 (0.47; 35.27)	0.192
11:01	05:05	03:01	254 (10.1)	4 (6.7)	0.64 (0.24; 1.69)	0.515
11:03	05:05	03:01	28 (1.1)	1 (1.7)	1.51 (0.14; 9.12)	0.497
12:01	05:05	03:01	53 (2.1)	1 (1.7)	0.79 (0.08; 4.46)	>0.999
13:01	01:03	06:03	209 (8.3)	5 (8.3)	1.00 (0.43; 2.39)	>0.999
13:02	01:02	06:04	118 (4.7)	6 (10.0)	2.26 (1.03; 5.30)	0.058
13:03	05:05	03:01	40 (1.6)	1 (1.7)	1.05 (0.10; 6.08)	0.623
16:01	01:02	05:02	90 (3.6)	4 (6.7)	1.92 (0.73; 5.00)	0.278
others			781 (31.1)